NEFL and amyloidosis: Based on the combined NfL data from the current studies, we could construct a hypothetical course of NfL levels over time from asymptomatic TTRv carriers who progress to asymptomatic ATTRv amyloidosis patients without neurological symptoms to symptomatic ATTRv amyloidosis patients with polyneuropathy and who subsequently receive treatment (Figure 3).